A Phase 2 interventional study of FOLFOX or FOLFIRI in Tumor, Colorectal, Organoids and Tumoroid, sponsored by St. Olavs Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by St. Olavs Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Colorectal Neoplasms with a site in Norway — 19 open to participants now, 35 under way, 6 of them phase 3. Colorectal Neoplasms · Norway.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, this one is the 39th largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 17 of the 34 other live ones, and was the 75th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →19 of the 82 studies in Colorectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
University of Edinburgh · Sites in Norway, United Kingdom
Ages 18+
Incyte Corporation · Sites in Norway, United States, Argentina and 19 more countries
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 40–75
Oncosyne AS · Sites in Norway
Ages 18+
GlaxoSmithKline · Sites in Norway, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 22 · Phase 3 19
First in 1983; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 172 across the 68 interventional studies, 427 across the 12 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
St. Olavs Hospital is the lead sponsor of 171 studies on the registry; 29 are open to participants now.
St. Olavs Hospital has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT06333392Vestre Viken Hospital TrustTotal Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | 2026-12 |
| NCT07255066University of EdinburghOptimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial | 2027-01 |
| NCT03494946Oslo University HospitalLiver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | 2027-01 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.
Objectives: The primary objective of this study is to test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. Secondary objectives are to describe the tumour response to treatment using efficacy measures and assess the progression-free survival and the overall survival, and assess the toxicity experienced by the participants. Exploratory objectives include basal research on tumouroids and optimisation of the functional assay to be compatible with clinical practice.
Primary endpoints: The primary endpoints are assessing feasibility:
Secondary endpoints: Secondary endpoints include efficacy in the form of Response Rates (RR) graded and measured using RECIST v1.1, including Objective Response Rate (ORR), Disease Control Rate (DCR) and Clinical Benefit Rate (CBR), as well as Duration of Response (DoR), Progression Free Survival (PFS), Progression Free Survival Rate at 6 months (PFSR) and Overall Survival (OS). Toxicity will be graded using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v.5.0).
Trial design and patient population: COSENSE-1 is an unblinded, phase II, single-armed, single-center, consent-based feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) that is incurable or not resectable with curative intent. Participants can proceed to the treatment cohort of the trial if standard of care treatment can be allocated within the timeframes given by the Norwegian national recommendations for the treatment of colorectal cancer. The study duration will be up to 36 months for each participant with treatment duration up to 6 months, and the study visit frequency will be one per participant.
Main inclusion criteria:
Main exclusion criteria:
Number of participants:
Approximately 148 patients will be screened to achieve:
Intervention: Oxaliplatin-based or irinotecan-based chemotherapy regimen based on patient-derived tumouroids as guide for clinical decision.
Ethical considerations:
For over two decades, both type of chemotherapy regimens (oxaliplatin-based and irinotecan-based) have been considered equal first-line treatment regimens for this patient group. In clinical practice as of today, no biomarkers are available to guide whether oxaliplatin-based or irinotecan-based chemotherapy will be most effective in treating the individuals' cancer disease. Therefore, treatment typically begins with either regimen, often influenced by local traditions or practices. Furthermore, effectiveness of the chosen regimen is monitored clinically and radiologically, and if efficacy is insufficient or toxicities are intolerable, patients are switched to the alternative regimen after 2-3 months. These months are significant for patients with already limited life expectancy. The COSENSE-1 trial offers a more rational approach by providing the most promising chemotherapy regimen upfront. The prerequisites for COSENSE-1, discards the risk of being allocated to inferior treatment compared to clinical practice, and assures similar time frames, safety and toxicity profiles as in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General conditions:
Women of and men must agree to use highly effective (defined in publicly available protocol)
Disease and treatment specific conditions:
Exclusion Criteria:
Treatment cannot be scheduled within 28 days from referral
Medical history:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOLFOX or FOLFIRI based on readout from patient-derived tumouroids (via biopsy)
Drug: FOLFOX or FOLFIRI
Treatment allocation from tumouroid readout
Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.
Rate of generating valid\* tumouroid response reports per patient included in the trial. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with respect to day 0 or 1.
Time frame: Up to 1 month
Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.
Rate of generating valid\* tumouroid response reports per patient with obtained tumour sample. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with resepect to day 0 or 1.
Time frame: Up to 1 month
Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.
What is the time from referral to start of allocated treatment
Time frame: Up to 1 month
Describe the tumour response to treatment using RECIST v.1.1
Objective Response Rate (ORR)
Time frame: Up to 48 months
Describe the tumour response to treatment using RECIST v.1.1
Disease Control Rate (DCR)
Time frame: Up to 48 months
Describe the tumour response to treatment using RECIST v.1.1
Clinical Benefit Rate (CBR), defined as the percentage of patients who had a complete response, partial response, or had stable disease for 6 months or more
Time frame: Up to 48 months
Describe the tumour response to treatment using RECIST v.1.1
Duration of Response (DoR)
Time frame: Up to 48 months
Assess progression free survival
Progression Free Survival (PFS), defined as the time from starting first-line treatment to the time of documentation of progressive disease (PD) according to RECIST v.1.1 on active therapy, determined failure of treatment strategy or death
Time frame: Up to 5 years
Assess progression free survival rate
Progression Free Survival Rate (PFSR), defined as the ratio of participants with PFS at 6 months
Time frame: Up to 6 months
Assess overall survival
Overall Survival
Time frame: Up to 5 years
Toxicity experienced in the trial
Incidence of grade 3-5 adverse events using CTCAE v.5.0
Time frame: Up to 2 years
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 31 months is below that.
Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.